HTCC as a highly effective polymeric inhibitor of SARS-CoV-2 and MERS-CoV
Aleksandra Milewska(Jagiellonian University), Krzysztof Pyrć(Jagiellonian University), Marek Ochman(Medical University of Silesia), Emilia Barreto-Durán(Jagiellonian University), Maciej Urlik(Medical University of Silesia), Krzysztof Szczubiałka(Jagiellonian University), Lunbiao Cui(Jiangsu Provincial Center for Disease Control and Prevention), Sylwia Rodziewicz‐Motowidło(University of Gdańsk), Maria Nowakowska(Jagiellonian University), Fengcai Zhu(Jiangsu Provincial Center for Disease Control and Prevention), Dan Liu(Yangtze University), Kevin Liu(Boston Children's Hospital), Ying Chi(China Three Gorges University), Jingxin Li(Beijing Tongren Hospital), Artur Szczepański(Jagiellonian University), Xiling Guo(Jiangsu Provincial Center for Disease Control and Prevention), Yiyue Ge(Jiangsu Provincial Center for Disease Control and Prevention)
Cited by 41
Related Papers
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|The Lancet Infectious Diseases|2020|1.5k
Co-infection with respiratory pathogens among COVID-2019 cases
|Virus Research|2020|637
Taxonomy of the order Bunyavirales: update 2019
|Archives of Virology|2019|398
Serum Cytokine and Chemokine Profile in Relation to the Severity of Coronavirus Disease 2019 in China
|The Journal of Infectious Diseases|2020|391
A Family Cluster of Infections by a Newly Recognized Bunyavirus in Eastern China, 2007: Further Evidence of Person-to-Person Transmission
|Clinical Infectious Diseases|2011|268